NASDAQ:KMPH Zevra Therapeutics - KMPH Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Zevra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Add Compare Share Share Today's Range N/A50-Day Range$4.12▼$6.2752-Week Range N/AVolume64,100 shsAverage Volume189,500 shsMarket Capitalization$200.47 millionP/E RatioN/ADividend YieldN/APrice Target$17.25 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Zevra Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside∞ Upside$17.25 Price TargetShort InterestHealthy4.38% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.44Based on 2 Articles This WeekInsider TradingAcquiring Shares$55,369 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.65) to ($0.68) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.07 out of 5 starsMedical Sector414th out of 986 stocksPharmaceutical Preparations Industry193rd out of 477 stocks 3.5 Analyst's Opinion Consensus RatingZevra Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.25, Zevra Therapeutics has a forecasted upside of ∞ from its current price of $0.00.Amount of Analyst CoverageZevra Therapeutics has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.38% of the float of Zevra Therapeutics has been sold short.Short Interest Ratio / Days to CoverZevra Therapeutics has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in Zevra Therapeutics has recently decreased by 5.52%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldZevra Therapeutics does not currently pay a dividend.Dividend GrowthZevra Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KMPH. Previous Next 2.5 News and Social Media Coverage News SentimentZevra Therapeutics has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Zevra Therapeutics this week, compared to 2 articles on an average week.Search Interest1 people have searched for KMPH on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Zevra Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zevra Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $55,369.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 1.10% of the stock of Zevra Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 19.39% of the stock of Zevra Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Zevra Therapeutics are expected to decrease in the coming year, from ($0.65) to ($0.68) per share. Previous Next See Top Rated MarketRank™ Stocks Here About Zevra Therapeutics (NASDAQ:KMPH) StockKemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.Read More Receive KMPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zevra Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address KMPH Stock News HeadlinesMarch 19, 2023 | americanbankingnews.comStockNews.com Begins Coverage on Zevra Therapeutics (NASDAQ:KMPH)March 17, 2023 | finance.yahoo.comZevra Therapeutics Announces Collaboration with RARE-X and the Sleep Consortium as Founding Member of New Sleep Data InitiativeMarch 23, 2023 | Oxford Club (Ad)My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.March 15, 2023 | finance.yahoo.comZevra Therapeutics Files Definitive Proxy Statement and Mails Letter to ShareholdersMarch 7, 2023 | finance.yahoo.comZevra Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Corporate UpdatesMarch 6, 2023 | finance.yahoo.comZevra Therapeutics to Present at 35th Annual Roth ConferenceMarch 1, 2023 | finance.yahoo.comZevra Therapeutics Begins Trading as ZVRAFebruary 28, 2023 | finance.yahoo.comZevra Therapeutics Reiterates Commitment to Rare Disease Community as New Corporate Council Member of the National Organization for Rare Disorders (NORD)March 23, 2023 | Oxford Club (Ad)My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.February 27, 2023 | finance.yahoo.comZevra Therapeutics, a Rare Disease Therapeutics Company, Files Preliminary ProxyFebruary 27, 2023 | finance.yahoo.comZevra Therapeutics to Report Fourth Quarter and Full-Year 2022 ResultsFebruary 24, 2023 | finance.yahoo.comZevra Therapeutics Announces Arimoclomol Research Featured in Two Poster Presentations at the 19th Annual WORLDSymposium™ 2023February 23, 2023 | finance.yahoo.comZevra Therapeutics Announces Two Abstracts Accepted for Presentation at the 19th Annual WORLDSymposium™ 2023February 22, 2023 | finance.yahoo.comKemPharm Announces Corporate Name Change to Zevra TherapeuticsFebruary 9, 2023 | finance.yahoo.comBreakeven On The Horizon For KemPharm, Inc. (NASDAQ:KMPH)February 5, 2023 | seekingalpha.comKemPharm: Now A Rare Disease Play, Upgrading To A Buy RatingFebruary 3, 2023 | bizjournals.comMeet KemPharm’s new CEO, a West Point grad who will lead the expansion into rare disease drugsJanuary 31, 2023 | finance.yahoo.comKemPharm Enhances Senior Management TeamJanuary 18, 2023 | finance.yahoo.comKemPharm Partners with the Hypersomnia Foundation to Support Sleep Disorder Research and AdvocacyJanuary 11, 2023 | finance.yahoo.comKemPharm Announces Promotion of Sven Guenther, Ph.D., to Chief Scientific Officer and Christal Mickle, M.A., to Chief Product Development OfficerJanuary 9, 2023 | finance.yahoo.comKemPharm Announces Board and Leadership Changes to Support its Transformation into a Leading Rare Disease CompanyDecember 24, 2022 | reuters.comKMPH.PH - KemPharm Inc | Stock Price & Latest News | ReutersDecember 21, 2022 | finance.yahoo.comKemPharm Announces Initiation of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH)November 29, 2022 | finance.yahoo.comKemPharm Announces Appointment of Christopher Posner as New Independent DirectorNovember 20, 2022 | finance.yahoo.comAnalysts Have Just Cut Their KemPharm, Inc. (NASDAQ:KMPH) Revenue Estimates By 11%November 18, 2022 | finance.yahoo.comKemPharm Receives FDA Orphan Drug Designation for Serdexmethylphenidate (SDX) for the Treatment of Idiopathic Hypersomnia (IH)November 16, 2022 | finance.yahoo.comKemPharm Third Quarter 2022 Earnings: Misses ExpectationsSee More Headlines Receive KMPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zevra Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address KMPH Company Calendar Last Earnings3/30/2022Today3/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KMPH CUSIPN/A CIK1434647 Webwww.kempharm.com Phone(321) 939-3416Fax319-665-2577Employees22Year FoundedN/APrice Target and Rating Average Stock Price Forecast$17.25 High Stock Price Forecast$20.00 Low Stock Price Forecast$10.00 Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,560,000.00 Net Margins-328.56% Pretax Margin-335.26% Return on Equity-16.12% Return on Assets-14.17% Debt Debt-to-Equity Ratio0.14 Current Ratio10.10 Quick Ratio10.10 Sales & Book Value Annual Sales$10.72 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow23.28 Book Value$3.63 per share Price / BookN/AMiscellaneous Outstanding Shares34,505,000Free Float34,125,000Market Cap$200.47 million OptionableOptionable Beta2.16 Key ExecutivesRichard W. PascoeChief Executive Officer & DirectorTravis C. MicklePresident & DirectorR. LaDuane CliftonChief Financial Officer, Secretary & TreasurerSven GuentherChief Scientific OfficerDaniel GalloSenior Vice President-Medical AffairsKey CompetitorsOrganigramNASDAQ:OGINature's Sunshine ProductsNASDAQ:NATRVera TherapeuticsNASDAQ:VERAALX OncologyNASDAQ:ALXOFoghorn TherapeuticsNASDAQ:FHTXView All CompetitorsInsiders & InstitutionsKovack Advisors Inc.Sold 2,110 shares on 2/22/2023Ownership: 0.310%Man Group plcBought 3,768 shares on 2/15/2023Ownership: 0.096%Jane Street Group LLCBought 31,977 shares on 2/15/2023Ownership: 0.093%Schonfeld Strategic Advisors LLCSold 13,600 shares on 2/15/2023Ownership: 0.047%Morgan StanleySold 7,140 shares on 2/15/2023Ownership: 0.030%View All Insider TransactionsView All Institutional Transactions KMPH Stock - Frequently Asked Questions Should I buy or sell Zevra Therapeutics stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zevra Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" KMPH shares. View KMPH analyst ratings or view top-rated stocks. What is Zevra Therapeutics' stock price forecast for 2023? 4 analysts have issued 1 year price objectives for Zevra Therapeutics' shares. Their KMPH share price forecasts range from $10.00 to $20.00. On average, they predict the company's stock price to reach $17.25 in the next year. View analysts price targets for KMPH or view top-rated stocks among Wall Street analysts. How were Zevra Therapeutics' earnings last quarter? Zevra Therapeutics, Inc. (NASDAQ:KMPH) announced its earnings results on Wednesday, March, 30th. The specialty pharmaceutical company reported ($0.08) EPS for the quarter, meeting the consensus estimate of ($0.08). Zevra Therapeutics had a negative trailing twelve-month return on equity of 16.12% and a negative net margin of 328.56%. What ETF holds Zevra Therapeutics' stock ? iShares Neuroscience and Healthcare ETF holds 4,480 shares of KMPH stock, representing 0.37% of its portfolio. What other stocks do shareholders of Zevra Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Zevra Therapeutics investors own include Sorrento Therapeutics (SRNE), Idera Pharmaceuticals (IDRA), SCYNEXIS (SCYX), AVEO Pharmaceuticals (AVEO), Aldeyra Therapeutics (ALDX), Exelixis (EXEL), BioCryst Pharmaceuticals (BCRX), Cara Therapeutics (CARA), DURECT (DRRX) and Paratek Pharmaceuticals (PRTK). When did Zevra Therapeutics IPO? (KMPH) raised $60 million in an initial public offering (IPO) on Thursday, April 16th 2015. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Cowen and Company and RBC Capital Markets served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer were co-managers. What is Zevra Therapeutics' stock symbol? Zevra Therapeutics trades on the NASDAQ under the ticker symbol "KMPH." Who are Zevra Therapeutics' major shareholders? Zevra Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Janney Montgomery Scott LLC (1.43%), Simplex Trading LLC (0.00%), Geode Capital Management LLC (0.90%), Retirement Planning Co of New England Inc. (0.86%), Susquehanna International Group LLP (0.00%) and Mystic Asset Management Inc. (0.51%). Insiders that own company stock include David S Tierney, R Laduane Clifton, Richard W Pascoe, Samuel J Braun, Tamara A Seymour and Travis C Mickle. View institutional ownership trends. How do I buy shares of Zevra Therapeutics? Shares of KMPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. How much money does Zevra Therapeutics make? Zevra Therapeutics (NASDAQ:KMPH) has a market capitalization of $0.00 and generates $10.72 million in revenue each year. How can I contact Zevra Therapeutics? Zevra Therapeutics' mailing address is 1180 Celebration Boulevard Suite 103, Celebration FL, 34747. The official website for the company is www.kempharm.com. The specialty pharmaceutical company can be reached via phone at (321) 939-3416, via email at jrando@tiberend.com, or via fax at 319-665-2577. This page (NASDAQ:KMPH) was last updated on 3/23/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.